当前位置: 首页 > 期刊 > 《医学信息》 > 2018年第4期
编号:13245459
阿托伐他汀治疗急性ST段抬高型心肌梗死合并高血压的效果分析(1)
http://www.100md.com 2018年1月29日 《医学信息》 2018年第4期
     摘 要:目的 探讨阿托伐他汀治疗急性ST段抬高型心肌梗死合并高血压患者的临床效果。方法 2016年12月~2017年1月我院内二科收治的82例急性ST段抬高型心肌梗死合并高血压患者,随机分为对照组和观察组,每组41例,对照组口服依那普利及氯沙坦钾片,观察组在对照组基础上加用阿托伐他汀,对比两组治疗前后效果分析。结果 观察组显效13例高于对照组5例(P<0.05)。治疗后观察组LVPW、LVEDD、LVEF和LVESD优于对照组,存在统计学意义(P<0.05)。观察组TC、LDL-C及CRP低于对照组,观察组HDL-C高于对照组,存在统计学意义(P<0.05);观察组SBP和Lp-PLA2低于对照组,观察组CO和CI高于对照组,存在统计学意义(P<0.05)。结论 阿托伐他汀能降低高血压并发ST段抬高型心肌梗死患者的血压及Lp-PLA2水平,改善脂代谢,能延缓心肌梗死后的心室重构进程,提高患者心脏功能。

    关键词:ST段抬高型急性心肌梗死;左心室收缩末期内径;左心室舒张末内径;左心室射血分数
, http://www.100md.com
    中图分类号:R542.2+2;R544 文献标识码:A DOI:10.3969/j.issn.1006-1959.2018.04.027

    文章编号:1006-1959(2018)04-0084-02

    Abstract:Objective To investigate the clinical effect of Atto vastatin in treating patients with acute ST-segment elevation myocardial infarction complicated with hypertension.Methods From December 2016 to January 2017,82 patients with acute ST-segment elevation myocardial infarction complicated with hypertension were treated in our hospital.They were randomly divided into two groups: control group(n=41)and observation group(n=41).The control group took enalapril and losartan potassium tablets orally,and the observation group was treated with Atto vastatin on the basis of the control group,the results were compared between the two groups before and after treatment.Results 13 cases in the observation group were more effective than 5 cases in the control group(P<0.05), LVEF and LVESD in the observation group were better than those in the control group,and there was statistical significance(P<0.05).The TC,LDL-C and CRP in the observation group were lower than those in the control group.The HDL-C in the observation group was higher than that in the control group, with statistical significance(P<0.05).The SBP and Lp-PLA2 in the observation group were lower than those in the control group,and the CO and CI in the observation group were higher than those in the control group,with statistical significance(P<0.05).Conclusion Atto vastatin can decrease blood pressure and Lp-PLA2 level,improve lipid metabolism, delay ventricular remodeling and improve cardiac function in patients with hypertension complicated with ST-segment elevation myocardial infarction.
, 百拇医药
    Key words:ST segment elevation acute myocardial infarction;Left ventricular end-systolic diameter;Left ventricular end diastolic diameter;Left ventricular ejection fraction

    急性ST段抬高型心肌梗死(ST-segment elevation myocardial infarction,STEMI)是因冠狀动脉病变引发冠状动脉供血急剧减少而导致的心肌缺血性坏死,是临床常见的急性心肌缺血性坏死[1]。近二十多年来,死亡率高,高血压并发STEMI的发生率居高不下,已经引起国内外医学研究者的广泛重视[2]。且高血压并发STEMI的并发症多、预后很差[3]。阿托伐他汀HMG-CoA还原酶选择性抑制剂,能降低心肌梗死的风险,对动脉粥样硬化的疗效较佳。被临床医生应用于高脂血症、冠心病的治疗。我科选取2016年12月~2017年1月内收治的82例STEMI合并高血压患者,应用阿托伐他汀治疗效果好,现报道如下。, 百拇医药(肖红)
1 2下一页